Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. Biopharmaceutical firm Retrophin Inc. (RTRX:NASDAQ) shares are trading much lower today as the co...
Streetwise Reports | August 26, 2019 |

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. ...
Streetwise Reports | November 25, 2019 |

Drone Technology Company Is in the Limelight Amid Data Security Concerns

As worries over drone data take center stage, Red Cat Holdings' blockchain technology offers security and integrity of data. Drone data security has become a hot issue. The Department of the Interior last fall grounded its 1,000-strong drone fleet and in Jan...
Streetwise Reports | February 13, 2020 |

Biopharma to Accelerate Alzheimer Trial Completion

The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report. In a March 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Axsome Therapeutics Inc. ...
Streetwise Reports | March 26, 2020 |

Torq Resources’ New Gold-Copper Project a Game Changer for Investors

Torq Resources ’ latest procurement in Chile is a transformative move for the company, whose team has worked diligently to build a presence in a region dominated by major mining operations. The newly announced acquisition of the Santa Cecilia project has est...
Denise Deveau | November 1, 2021 |

Buzz on the Bullboards: Three newsmakers during TSX’s rebound

The TSX experienced a roller-coaster week, starting with notable losses but ending with a robust rebound, leading to significant gains. This positive shift has supported investor confidence, proving that it is important to stay updated with recent developments. Let&CloseC...
Jonathon Brown | August 1, 2024 |

Should you buy SLV the silver ETF?

Charts presented in this report are courtesy Stockcharts.com. Featured is the daily bar chart for SLV. Price has risen for five days, but volume has not yet supported the rise. This lack of volume could be because more and more people are becoming aware of the f...
Peter Degraaf | October 28, 2012 |

Royalties Face Mine Problems and Tax Bills

Royal Gold Inc. (RGLD:NASDAQ; RGL:TSX, US$115.82) (115.82) is facing uncertainty on its main asset, the Mount Milligan copper-gold mine in British Columbia, whose stream accounts for nearly 30% of the company's revenue and its book value. The mine has experienced lower...
Streetwise Reports | December 20, 2019 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |

The Die Is Cast

One of my good friends from the 1980s and 1990s was the late Ian McAvity, a superb technical analyst, a founder of Central Fund of Canada, a Bay Street Mover and, most importantly, a humble and thoroughly enjoyable man. He was the first newsletter writer that I came acros...
Streetwise Reports | February 25, 2020 |
1 2 3 4 5 6 7 8 9 10 ...